213 related articles for article (PubMed ID: 27311087)
1. [ANMCO Position paper: Diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance].
Gulizia MM; Colivicchi F; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
G Ital Cardiol (Rome); 2016 Jun; 17(6):447-55. PubMed ID: 27311087
[TBL] [Abstract][Full Text] [Related]
2. ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance.
Gulizia MM; Colivicchi F; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
Eur Heart J Suppl; 2017 May; 19(Suppl D):D55-D63. PubMed ID: 28751834
[TBL] [Abstract][Full Text] [Related]
3. [ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome].
Colivicchi F; Gulizia MM; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
G Ital Cardiol (Rome); 2016 Jun; 17(6):456-61. PubMed ID: 27311088
[TBL] [Abstract][Full Text] [Related]
4. [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].
Borghi C; Filardi PP
G Ital Cardiol (Rome); 2015; 16(7-8 Suppl 1):3S-14S. PubMed ID: 26442834
[TBL] [Abstract][Full Text] [Related]
5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
6. Lipid management with statins. The lower the better?
Laufs U; Liao JK; Böhm M
Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
[TBL] [Abstract][Full Text] [Related]
7. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
Jacobson TA
Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
[TBL] [Abstract][Full Text] [Related]
8. [Hyperlipidemia: decreasing lipid values and effects of statins].
Mathes P
Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
[No Abstract] [Full Text] [Related]
9. Statin intolerance - a question of definition.
Algharably EA; Filler I; Rosenfeld S; Grabowski K; Kreutz R
Expert Opin Drug Saf; 2017 Jan; 16(1):55-63. PubMed ID: 27645111
[TBL] [Abstract][Full Text] [Related]
10. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
[TBL] [Abstract][Full Text] [Related]
11. When a statin fails.
Med Lett Drugs Ther; 2009 Jul; 51(1317):58-60. PubMed ID: 19636290
[No Abstract] [Full Text] [Related]
12. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
13. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
[TBL] [Abstract][Full Text] [Related]
14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
16. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
18. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
19. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
Capriotti T
Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
[No Abstract] [Full Text] [Related]
20. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
